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Abstract
Background: Human populations that are naturally subjected to Plasmodium infection do not acquire complete
protection against the liver stage of this parasite despite prolonged and frequent exposure. However, sterile
immunity against Plasmodium liver stage can be achieved after repeated exposure to radiation attenuated
sporozoites. The reasons for this different response remain largely unknown, but a suppressive effect of blood
stage Plasmodium infection has been proposed as a cause for the lack of liver stage protection.
Methods: Using Plasmodium yoelii 17XNL, the response generated in mice subjected to daily infective bites from
normal or irradiated mosquitoes was compared. The effect of daily-infected mosquito bites on mice that were
previously immunized against P. yoelii liver stage was also studied.
Results: It was observed that while the bites of normal infected mosquitoes do not generate strong antibody
responses and protection, the bites of irradiated mosquitoes result in high levels of anti-sporozoite antibodies and
protection against liver stage Plasmodium infection. Exposure to daily infected mosquito bites did not eliminate the
protection acquired previously with a experimental liver stage vaccine.
Conclusions: Liver stage immunity generated by irradiated versus normal P. yoelii infected mosquitoes is essentially
different, probably because of the blood stage infection that follows normal mosquito bites, but not irradiated.
While infective mosquito bites do not induce a protective liver stage response, they also do not interfere with
previously acquired liver stage protective responses, even if they induce a complete blood stage infection.
Considering that the recently generated anti-malaria vaccines induce only partial protection against infection, it is
encouraging that, at least in mouse models, immunity is not negatively affected by subsequent exposure and
infection with the parasite.
Background
Malaria is a widespread mosquito-borne infectious dis-
ease that kills almost one million persons per year, most
of which are children. Growing scientific knowledge and
the recent malaria research trend provide unparalleled
opportunities to develop a malaria vaccine. Although
the subunit vaccines are the most advanced in research
pipelines and field clinical trials [1], an effective and
focused effort prevails in order to develop an attenuated
sporozoite-based vaccine [2,3], once the protective
immunity produced by attenuated sporozoites is stron-
ger and more unswerving than that induced by subunit
vaccination [4]. Immunization with irradiated Plasmo-
dium sporozoites grants protection against inoculation
with non-attenuated sporozoites in mice models and
humans [5,6]. However, individuals in malaria endemic
regions do not develop fully protective immune
responses against Plasmodium liver stage infections
even if exposed to more than two infective mosquito
bites daily [7,8], as is the case in high transmission areas
[9]. Using a mouse model, a previous study showed that
the mode of irradiated sporozoite delivery: daily mos-
quito bites (as in endemic areas) versus few large doses
of sporozoites (as in immunization protocols) does not
affect the generation of protective liver stage immunity
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any medium, provided the original work is properly cited.[10]. In this work, it was assessed whether the daily bites
of non-irradiated infected mosquitoes would also induce
a protective liver stage immune response, similar to that
induced by irradiated infected mosquito bites. This
situation would be analogous to the circumstances of
humans in high-transmission malaria endemic areas,
where people are subjected to daily bites of infected
mosquitoes [9].
In this work, it was observed that daily bites of non-
irradiated infected mosquitoes do not induce liver stage
protection, while the daily bites of irradiated mosquitoes
do. This result again confirms the concordance of obser-
vations in mice and in humans regarding liver stage
immunity and focuses the questions about generation of
liver stage protection on the differences between infec-
tion generated by irradiated versus normal sporozoites.
Since the use of partially protective malaria liver stage
vaccines in the field may soon be a reality [11], how
would infected mosquito bites affect the immune
response and protection induced by the vaccine
becomes a highly relevant question. An enhancing effect
caused by additional boosting liver stage antigens could
be expected, however, an inhibition of the vaccine-
induced protection has also been proposed [12]. There-
fore, a mouse model was used to test whether the bites
of infected mosquitoes could affect previously acquired
liver stage immunity. Interestingly, it was found that
after immunization of the mice, daily bites of infected
mosquitoes do not significantly affect the liver stage
protective response.
Methods
Parasites, mosquitoes and mouse immunizations
Anopheles stephensii mosquitoes were maintained as
d e s c r i b e d[ 1 3 ]a n di n f e c t e dw i t hP. yoelii 17XNL. This
parasite line has been grown for over ten years without
cloning and is the same used in previous work [10].
Irradiated mosquitoes were generated by exposure to 12
krad (120 Gy) of g-irradiation (MDS Nordion Gamma-
cell 1000 Elite). Female Swiss-Webster mice (NIH,
Bethesda MD) were used for all experiments. For the
partial immunization, each mouse was injected intrave-
nously with 75,000 P. yoelii 17XNL irradiated (12 krad)
sporozoites dissected from the salivary glands of infected
mosquitoes, followed two weeks later with a dose of
50,000. For daily mosquito bites, each mouse had two
mosquitoes feed on the tail for 3 min. This was repeated
daily for 6 weeks. Parasitaemia was followed regularly
using thin blood smears from a drop of tail blood.
Immunofluorescence titration of serum antibodies
For titration of P. yoelii-specific antibody levels, 10
4 sali-
vary-gland sporozoites in each well were air-dried on
glass multiwell IFA slides. Mouse serum was titrated
and primary antibody bound to sporozoites was detected
using FITC-labelled antimouse IgG (Sigma). A monoclo-
nal P. yoelii CS-specific antibody (2F6) was used as a
positive control (kindly provided by Dr. Photini Sinnis,
NYU).
Challenge and quantitative real-time PCR
Challenge of mice was performed in groups of five mice
by i.v. injection of 10
4 (non-irradiated) P. yoelii 17XNL
GFP sporozoites [14], freshly dissected from mosquito
salivary glands. Forty hours later, livers were harvested,
total RNA was isolated, and malaria infection was quan-
tified using reverse transcription followed by real-time
PCR with primers that recognize GFP-specific
sequences: 5’-GTC AGT GGA GAG GGT GAA GG-3’
and 5’-ACT TCA GCA CGT GTC TTG TAG TTC-3’.
Reaction was run for 40 cycles. Threshold cycle is the
fractional cycle at which the fluorescence signal passes
the threshold, which was set up at 50% of the maximal
fluorescence signal.
Statistical analysis
Data were analyzed using Prism (v. 4.0c, GraphPad).
ANOVA test was performed as mentioned. Statistics
were considered significant if P < 0.05.
Results and discussion
To compare the responses of mice to daily normal or
irradiated mosquito bites, a protocol previously shown
to induce protection in mice when mosquitoes infected
with the non-lethal parasite P. yoelii 17XNL are irra-
diated was followed [10]. The first group received an
immunization regimen of daily bites from two irradiated
mosquitoes to mimic an entomological inoculation rate
found in regions of very high transmission [9,15]. The
second group received identical treatment, but mice
were bitten by non-irradiated infected mosquitoes. For
both groups, each mouse had two mosquitoes feed on
her tail for three minutes. This was repeated daily for
six weeks (Figure 1).
To study whether the immune response induced by a
vaccine can be affected by subsequent bites of infected
mosquitoes, we immunized mice with two doses of
radiation-attenuated sporozoites. This immunization
protocol that induces only partial liver stage protection
was purposely chosen to reflect the situation with cur-
rent human liver stage vaccine prototypes [11]. After
immunization, mice were subjected or not to daily bites
of infected mosquitoes, as described above (Figure 1).
One week after the last mosquito bite a small volume
of serum was obtained from each mouse to determine
anti-sporozoite antibody levels and seven weeks later
mice were challenged with non-irradiated P. yoelii spor-
ozoites to determine liver stage protection.
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confirming that irradiation of sporozoites and mosqui-
toes was effective; no blood stage infection was found in
the group subjected to the bites of irradiated mosquitoes
or the group immunized with irradiated sporozoites that
did not receive mosquito bites. The data also show that
mosquito bites induce a delayed development and lower
levels of parasitaemia in mice that were previously
immunized with irradiated sporozoites compared to
non-immunized mice, probably reflecting the lower liver
stage infection levels in the partially immunized mice
(Figure 2).
When the levels of anti-sporozoite antibodies were
determined, we observed that mice subjected to the
bites of irradiated, infected mosquitoes develop signifi-
cantly higher levels of antibodies compared to mice sub-
jected to the bites of normal infected mosquitoes. It is
important to note that both groups of mice had received
equal numbers of mosquito bites and it is, therefore,
expected that each group had received equal numbers of
sporozoites.
Antibody levels in the groups of mice that were
immunized with two doses of the irradiated sporozoite
vaccine followed or not by the bites of normal infected
mosquitoes showed no significant differences in their
anti-sporozoite antibody levels, suggesting that after
immunization, the antibody levels are not affected by
the bites of infected mosquitoes (Figure 3), even if the
mice developed a full blood stage infection (Figure 2).
To study the level of immunization acquired by the
different groups of mice, each mouse was challenged
Irradiated 
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Normal 
mosquito bites
Immunized
Immunized + normal 
mosquito bites
Ͳϰ ͲϮ Ϭ Ϯ ϰ ϲ ϴ ϭϬ ϭϮ ϭϰ
Time (weeks)
Figure 1 Experiment schedule. Four groups of five mice received
different immunizations and were subjected to the bites of
irradiated or normal infected mosquito bites as indicated. Two
groups were immunized by intravenous injection of two doses of
irradiated sporozoites two weeks apart (represented by crosses in
the figure). After another two weeks, three of the four groups were
subjected to two daily bites of infected mosquitoes, irradiated
(dashed line) or not (continuous line) for six weeks. One week later
(black circles), a small volume of serum was extracted from each
mouse to determine anti-sporozoite antibody levels (results shown
in Figure 3). Eight weeks later mice were challenged (white circles)
and liver stage infection detected with real-time PCR (results shown
in Table 1).
Figure 2 Determination of parasitaemia. Parasitaemia was
determined in peripheral blood in all groups of mice every other
day, starting ten days after the beginning of daily mosquito bites.
Average parasitaemias are shown for each group. Parasitaemia in
the group subjected to normal mosquito bites (black squares) and
immunized followed by normal mosquito bites (black circles) are
shown. In the groups subjected to irradiated mosquito bites (white
circles) and immunized control (white squares) no infected
erythrocytes were detected. Error bars represent standard deviation
within groups of mice (*, P < 0.05; **, P < 0.01, when comparing
mice subjected to normal mosquito bites and immunized followed
by normal mosquito bites mice using ANOVA).
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Figure 3 Anti-sporozoite antibody titres.S e r u mf r o me a c h
mouse was serially diluted and used to stain P. yoelii sporozoites.
The titers represent the inverse of the highest dilution at which
sporozoites could still be detected. Each circle represents an
individual mouse. Significant differences between the group of
normal mosquito bite and the other groups were found (P < 0.05)
when comparing with ANOVA).
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important to use a P. yoelii strain that allows us to dif-
ferentiate the challenge parasites from parasites (in liver
or blood stage forms) that were inoculated before by
either the immunization protocols or the mosquito
bites. This is possible analysing the livers of challenged
mice using real-time PCR to amplify the GFP sequence
present only the challenge sporozoites. This technique is
not as sensitive as the conventional RT-PCR used for
detection of liver stage infection, which amplifies
sequences within the 18S rRNA that are very abundant
in the parasite [16].
Mice were challenged 14 weeks after being subjected
to the first infected mosquito bite, when blood stage
parasitaemia was undetectable. It was found that, while
the liver stages of the GFP challenge sporozoites were
not detectable in mice subjected to irradiated infected
mosquito bites, mice that had been bitten by normal
infected mosquitoes developed a detectable liver stage
infection (Table 1). These results indicate a higher level
of liver stage protection in mice subjected to irradiated
infected mosquito bites. In this study the challenge was
performed by i.v. injection of sporozoites, which is dif-
ferent from the natural environment, where mosquito
bite inoculation would deposit sporozoites in the skin of
the host. Despite these differences, the results observed
in mice reflect the situation of humans, which are also
protected by the bites of irradiated infected mosquitoes
[5], but are not protected by natural exposure to
infected mosquito bites [7]. It should be noted that this
study was performed with two P. yoelii-infected mos-
quito bites per day, which is considered a high transmis-
sion rate and, therefore, it is not possible to extrapolate
the results to lower frequencies of transmission, to a
situation with concurrent bites of infected and unin-
fected mosquitoes or to infection with different strains
of Plasmodium, which would reflect more accurately the
conditions in malaria-endemic areas. In particular, the
degree of variability of Plasmodium strains that is found
in the field may interfere with the protection induced by
irradiated infected mosquitoes.
In groups of mice that were immunized with irra-
diated sporozoites, subsequent infected mosquito bites,
which caused a patent blood stage infection (Figure 2),
did not induce a loss of the protection acquired with
the experimental vaccination (Table 1). These results
indicate that liver stage protection induced by irradiated
sporozoites is not significantly affected by subsequent
infection in mice. It is important to note that the groups
of mice that were partially immunized with irradiated
sporozoites probably developed a low-level liver stage
infection. However, this level of infection is not detected
by the GFP RT-PCR used in this assay.
Taken together, these data indicate that the generation
of liver stage immunity against malaria is greatly depen-
dent on whether the mosquitoes that transmit infection
are irradiated or not. For both mice and humans, it has
been extensively demonstrated that irradiated sporo-
zoites induce a protective immune response [5,6], how-
ever, what remains unclear is why normal liver stage
infection does not induce comparable protection. The
possibility that low doses of sporozoites delivered in the
skin by mosquito bites could induce tolerance to this
stage of the parasite has been discarded in the mouse
model [10]. It has been also proposed that the subse-
quent blood stage infection that follows the liver infec-
tion interferes with the generation of protection to the
liver stage [12], a mechanism that could underlie the
lack of protection observed in mice beaten by infective
mosquitoes. It is possible that the high inflammatory
immune response that blood stage infection generates
could affect the establishment of a competent liver stage
memory response that would be maturing at the same
time as the blood stage is at its peak. It is also possible
that the aborted liver infection that takes place with
irradiated sporozoites generates a more protective
immune response compared to liver infection by regular
sporozoites. Previous experiments in mice suggest that
this is not the case, because the liver stage response was
found to be similar in mice infected with irradiated
sporozoites compared to mice infected with normal
sporozoites and treated to inhibit blood stage infection
[12]. However, in this work [12] the response was only
m e a s u r e df o rC Sp r o t e i na n di ti sp o s s i b l et h a tt h e
immune response to other proteins involved in Plasmo-
dium liver stage protection [17] could be different when
induced by irradiated versus regular sporozoites.
T h ea n a l y s i so fm i c et h a tw e r ef i r s tp a r t i a l l yi m m u -
nized with irradiated sporozoites and then subjected or
not to infected mosquito bites indicates that liver stage
protection was not lost after infective mosquito bites
that result in blood stage infection. Since the mice were
only partially protected, a full blood stage infection took
place after mice were bitten by infective mosquitoes.
This allowed us to analyze the effect of blood stage
Table 1 Protection against challenge
Mice experimental
conditions
Threshold cycle (Ct) in
real time-PCR
Number of mice
(protected/total)
Irradiated mosquito
bites
> 40 (3/3)
Normal mosquito
bites
17 ± 0.85 (0/3)
Immunized > 40 (3/3)
Immunized + normal
mosquito bites
> 40 (3/3)
Groups of mice were challenged with 10
4 P. yoelii-GFP sporozoites injected
intravenously. Real-time PCR was run for 40 cycles, therefore Ct > 40 indicates
no detection of parasite in the liver.
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the vaccination. Contrarily to the immune suppression
described when blood stage infection takes place right
after the liver stage [12], the protection induced by the
vaccination in our mice was not lost after blood stage
infection that occurred four weeks after the first immu-
nization (two weeks after the last immunization). These
results suggest that after establishment of the protective
liver stage immune response, this response is not signifi-
cantly affected by subsequent blood stage infection.
Conclusions
The results presented show that the liver stage immunity
generated in response to irradiated versus normal P. yoe-
lii infected mosquitoes is essentially different: while irra-
diated mosquitoes induce a protective immune response
with high levels of anti-sporozoite antibodies, normal
infected mosquitoes do not generate protection and only
low levels of specific antibodies. This situation reflects
the response of humans observed both in vaccination
trials, where irradiated mosquito bites induce protection,
and in the field, where years of constant re-infections do
not result in sterile protection against the liver stage. The
direct comparison of the human immune response to
normal versus irradiated mosquito bites is not possible
because the conditions of exposure to infective mosquito
bites in the field are very different from experimental
exposure to irradiated mosquito bites. In directly com-
paring the response generated by irradiated or non-irra-
diated infected mosquito bites, this work indicates that
the mosquito irradiation is the only essential variable
needed to generate protective liver stage response.
While infective mosquito bites do not induce a protec-
tive liver stage response, they also do not interfere with
previously acquired liver stage protective responses,
even if they induce a complete blood stage infection.
Considering that the recently generated anti-malaria
vaccines induce only partial protection against infection,
it is encouraging that, at least in mouse models, immu-
nity is not negatively affected by subsequent exposure
and infection with the parasite.
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